Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Description

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

Conditions

Lupus Nephritis

Talk to us

Study Overview

On this page

Study Details

Study overview

The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

An Adaptive, Randomized, Double-blind, Dose Exploration, Parallel Group, Placebo Controlled, Multicenter Phase 2 Trial to Evaluate the Efficacy, Safety and Tolerability of LNP023 in Combination With Standard-of-care With and Without Oral Corticosteroids in Patients With Active Lupus Nephritis Class III-IV, +/- V

Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

Condition
Lupus Nephritis
Intervention / Treatment

-

Contacts and Locations

Phoenix

Novartis Investigative Site, Phoenix, Arizona, United States, 85016

Hinsdale

Novartis Investigative Site, Hinsdale, Illinois, United States, 60521

Baltimore

Novartis Investigative Site, Baltimore, Maryland, United States, 21287

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Novartis Pharmaceuticals,

    Novartis Pharmaceuticals, STUDY_DIRECTOR, Novartis Pharmaceuticals

    Study Record Dates

    2028-03-13